Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 Million
YANTAI, China, Aug. 27, 2024 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments. During the reporting period, the company's total revenue was RMB 363 million, up 39% year-over-year. In this, the revenue from product sales wasRMB 332 million,...
Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
YANTAI, China, Dec. 27, 2023 /PRNewswire/ -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA): one is BA1105, an innovat...
First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection
YANTAI, China, Oct. 30, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) inChina has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China. Nivolumab is a mo...
Boan Biotech's BA1202 Approved for Clinical Trial
-The First Novel CEA/CD3 Bispecific Antibody in China- YANTAI, China, May 16, 2023 /PRNewswire/ -- Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation ofChina's National Medical Products A...
Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech's Dulaglutide Injection BA5101 in China
YANTAI, China, May 15, 2023 /PRNewswire/ -- Boan Biotech today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company's Dulaglutide Injection (BA5101) inChina. BA5101 is a biosimilar of Trulicity®, used...
First Subject Enrolled in Boan Biotech's International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102
YANTAI, China, May 4, 2023 /PRNewswire/ -- Boan Biotech today announced that an international multi-center Phase 3 clinical study for its in-house developed Denosumab Injection (BA6101; BA1102) has been initiated inEurope, the United States, and Japan, and recently the first patient in (FPI) was ...
Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil
YANTAI, China, April 11, 2023 /PRNewswire/ -- Boan Biotech today announced that Brazil's Agência Nacional de Vigilância Sanitária (ANVISA) has accepted the company's Biologics License Application (BLA) for Boyounuo® (Bevacizumab Injection). Envisioned to be "a leading global biopharmaceutical co...
Boan Biotech Announces 2022 Financial Results
Showing accelerated innovation and strong 225% revenue growth YANTAI, China, March 27, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2022 financial results and recent business developments. 2022 business highlights * Record high in revenue: In 2022, Boan Biotech's revenue was...
